Johnson & Johnson annual asset turnover
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson Asset Turnover Growth & History (JNJ)
Johnson & Johnson's asset turnover was 0.50 for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | 0.50 | −0.01 | −2.80% |
| 2024 | 2024-12-29 | 0.51 | 0.03 | +6.48% |
| 2023 | 2023-12-31 | 0.48 | 0.05 | +10.80% |
| 2022 | 2023-01-01 | 0.43 | −0.01 | −1.85% |
| 2021 | 2022-01-02 | 0.44 | −0.06 | −11.14% |
| 2020 | 2021-01-04 | 0.50 | −0.03 | −6.00% |
| 2019 | 2019-12-29 | 0.53 | 0.00 | +0.45% |
| 2018 | 2018-12-30 | 0.53 | 0.01 | +2.67% |
| 2017 | 2017-12-31 | 0.51 | −0.01 | −2.17% |
| 2016 | 2017-01-01 | 0.52 | −0.01 | −1.46% |
| 2015 | 2016-01-03 | 0.53 | −0.03 | −5.99% |
| 2014 | 2014-12-28 | 0.57 | 0.00 | +0.66% |
| 2013 | 2013-12-29 | 0.56 | −0.01 | −1.87% |
| 2012 | 2012-12-30 | 0.57 | −0.03 | −4.74% |
| 2011 | 2012-01-01 | 0.60 | −0.02 | −3.66% |
| 2010 | 2011-01-02 | 0.62 | −0.07 | −9.56% |
| 2009 | 2010-01-03 | 0.69 | — | — |
Johnson & Johnson quarterly asset turnover
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Asset turnover | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | 0.50 | 0.01 | +2.59% |
| Q1 2026 | 2026-03-29 | 0.49 | −0.00 | −0.04% |
| Q4 2025 | 2025-12-28 | 0.50 | −0.01 | −2.80% |
| Q3 2025 | 2025-09-28 | 0.50 | −0.01 | −2.50% |
| Q2 2025 | 2025-06-29 | 0.48 | 0.02 | +4.20% |
| Q1 2025 | 2025-03-30 | 0.49 | 0.02 | +4.96% |
| Q4 2024 | 2024-12-29 | 0.51 | 0.03 | +6.48% |
| Q3 2024 | 2024-09-29 | 0.51 | 0.02 | +3.81% |
| Q2 2024 | 2024-06-30 | 0.46 | 0.02 | +4.19% |
| Q1 2024 | 2024-03-31 | 0.47 | 0.03 | +7.52% |
| Q4 2023 | 2023-12-31 | 0.48 | 0.05 | +10.80% |
| Q3 2023 | 2023-10-01 | 0.49 | — | — |
| Q2 2023 | 2023-07-02 | 0.45 | — | — |
| Q1 2023 | 2023-04-02 | 0.43 | — | — |
| Q4 2022 | 2023-01-01 | 0.43 | — | — |
| Q3 2021 | 2021-10-03 | 0.52 | 0.02 | +4.18% |
| Q2 2021 | 2021-07-04 | 0.51 | 0.00 | +0.06% |
| Q1 2021 | 2021-04-04 | 0.51 | −0.03 | −6.17% |
| Q4 2020 | 2021-01-04 | 0.50 | −0.03 | −5.23% |
| Q3 2020 | 2020-09-27 | 0.50 | −0.03 | −5.59% |
| Q2 2020 | 2020-06-28 | 0.51 | −0.01 | −1.96% |
| Q1 2020 | 2020-03-29 | 0.54 | 0.01 | +1.93% |
| Q4 2019 | 2019-12-29 | 0.53 | 0.00 | +0.45% |
| Q3 2019 | 2019-09-29 | 0.53 | 0.00 | +0.44% |
| Q2 2019 | 2019-06-30 | 0.52 | 0.00 | +0.04% |
| Q1 2019 | 2019-03-31 | 0.53 | 0.01 | +1.96% |
| Q4 2018 | 2018-12-30 | 0.53 | 0.01 | +2.67% |
| Q3 2018 | 2018-09-30 | 0.52 | 0.02 | +4.05% |
| Q2 2018 | 2018-07-01 | 0.52 | 0.03 | +5.63% |
| Q1 2018 | 2018-04-01 | 0.52 | 0.01 | +1.66% |
| Q4 2017 | 2017-12-31 | 0.51 | −0.01 | −2.17% |
| Q3 2017 | 2017-10-01 | 0.50 | −0.02 | −3.99% |
| Q2 2017 | 2017-07-02 | 0.50 | −0.03 | −4.93% |
| Q1 2017 | 2017-04-02 | 0.51 | −0.02 | −3.13% |
| Q4 2016 | 2017-01-01 | 0.52 | −0.01 | −1.46% |
| Q3 2016 | 2016-10-02 | 0.52 | −0.01 | −1.54% |
| Q2 2016 | 2016-07-03 | 0.52 | −0.02 | −3.07% |
| Q1 2016 | 2016-04-03 | 0.53 | −0.03 | −5.68% |
| Q4 2015 | 2016-01-03 | 0.53 | −0.03 | −5.99% |
| Q3 2015 | 2015-09-27 | 0.53 | −0.04 | −7.52% |
| Q2 2015 | 2015-06-28 | 0.54 | −0.03 | −5.07% |
| Q1 2015 | 2015-03-29 | 0.56 | −0.00 | −0.44% |
| Q4 2014 | 2014-12-28 | 0.57 | 0.00 | +0.66% |
| Q3 2014 | 2014-09-28 | 0.57 | 0.00 | +0.20% |
| Q2 2014 | 2014-06-29 | 0.57 | −0.02 | −2.81% |
| Q1 2014 | 2014-03-30 | 0.56 | −0.01 | −2.19% |
| Q4 2013 | 2013-12-29 | 0.56 | −0.01 | −1.87% |
| Q3 2013 | 2013-09-29 | 0.57 | 0.00 | +0.39% |
| Q2 2013 | 2013-06-30 | 0.58 | 0.01 | +2.40% |
| Q1 2013 | 2013-03-31 | 0.58 | −0.00 | −0.41% |
| Q4 2012 | 2012-12-30 | 0.57 | −0.03 | −4.74% |
| Q3 2012 | 2012-09-30 | 0.57 | −0.04 | −6.85% |
| Q2 2012 | 2012-07-01 | 0.57 | −0.05 | −8.20% |
| Q1 2012 | 2012-04-01 | 0.58 | −0.04 | −6.00% |
| Q4 2011 | 2012-01-01 | 0.60 | −0.02 | −3.66% |
| Q3 2011 | 2011-10-02 | 0.61 | −0.05 | −6.86% |
| Q2 2011 | 2011-07-03 | 0.62 | −0.08 | −10.94% |
| Q1 2011 | 2011-04-03 | 0.62 | −0.08 | −12.06% |
| Q4 2010 | 2011-01-02 | 0.62 | — | — |
| Q3 2010 | 2010-10-03 | 0.66 | — | — |
| Q2 2010 | 2010-07-04 | 0.70 | — | — |
| Q1 2010 | 2010-04-04 | 0.70 | — | — |
Johnson & Johnson asset turnover trends
Over the last five fiscal years, Johnson & Johnson's asset turnover increased from 0.50 to 0.50, a change of 0.00. The latest reported quarter, Q2 2026, shows 0.50.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
